Efficacy of three-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus

被引:6
作者
Wu, Fei-Xiang [1 ,2 ,3 ]
Lu, Hui-Rong [4 ]
Zhu, Shao-Liang [1 ]
Li, Zi-Hui [1 ]
Zou, Ling [1 ]
Bai, Tao [1 ]
Chen, Jie [1 ]
Yang, Tian-Bo [1 ]
Liang, Shi-Xiong [4 ,5 ]
机构
[1] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Hepatobiliary Surg, Nanning, Peoples R China
[2] Guangxi Liver Canc Diag & Treatment Engn & Tech R, Nanning, Peoples R China
[3] Minist Educ, Key Lab Early Prevent & Treatment Reg High Freque, Shanghai, Peoples R China
[4] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Radiat Oncol, Nanning, Peoples R China
[5] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Radiat Oncol, 507 Zhengmin Rd, Shanghai 200433, Peoples R China
关键词
hepatocellular carcinoma; portal vein tumor thrombus; three-dimensional conformal radiotherapy; transarterial chemoembolization; overall survival; RADIATION-THERAPY; INVASION; FEATURES; DESIGN; TRIALS;
D O I
10.2147/OTT.S113161
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective: The current study aimed to evaluate the efficacy and outcomes of three-dimensional conformal radiotherapy (3DCRT) combined with transarterial chemoembolization (TACE) for treating patients with hepatocellular carcinoma involving portal vein tumor thrombus. Methods: Between January 2000 and December 2013, a total of 182 hepatocellular carcinoma patients with portal vein tumor thrombus were retrospectively analyzed: 68 patients were treated by 3DCRT alone (group A), 74 by TACE alone (group B), and 40 by a combination of 3DCRT + TACE (group C). The overall survival (OS) of the three groups was compared using the Kaplan-Meier method. The independent predictors of survival were identified using multivariate analysis. Results: The total effective rate (complete response + partial response) among all patients was 44% (80/182). The objective response rate (complete response + partial response) was higher in group C than in group A or B, but the differences were not significant. OS rates at 1, 2, and 3years were significantly higher in group C than in group A or B (P<0.05), while OS rates were similar between groups A and B. Multivariate analysis identified serum levels of alpha-fetoprotein <400 ng/mL and the use of 3DCRT + TACE as independent predictors of better OS. Conclusion: These results suggest that combining 3DCRT with TACE may provide better OS than either technique alone in hepatocellular carcinoma patients with portal vein tumor thrombus.
引用
收藏
页码:7141 / 7147
页数:7
相关论文
共 41 条
[1]   Efficacy of a Hepatectomy and a Tumor Thrombectomy for Hepatocellular Carcinoma with Tumor Thrombus Extending to the Main Portal Vein [J].
Ban, Daisuke ;
Shimada, Kazuaki ;
Yamamoto, Yusuke ;
Nara, Satoshi ;
Esaki, Minoru ;
Sakamoto, Yoshihiro ;
Kosuge, Tomoo .
JOURNAL OF GASTROINTESTINAL SURGERY, 2009, 13 (11) :1921-1928
[2]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[3]  
Cheng SQ, 2007, HEPATO-GASTROENTEROL, V54, P499
[4]   Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong [J].
Cheung, T. -K. ;
Lai, C. -L. ;
Wong, B. C. -Y. ;
Fung, J. ;
Yuen, M. -F. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (04) :573-583
[5]   Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis [J].
El-Serag, Hashem B. ;
Rudolph, Lenhard .
GASTROENTEROLOGY, 2007, 132 (07) :2557-2576
[6]   Radiation Therapy for Hepatocellular Carcinoma [J].
Feng, Mary ;
Ben-Josef, Edgar .
SEMINARS IN RADIATION ONCOLOGY, 2011, 21 (04) :271-277
[7]   Chemoembolization of hepatocellular carcinoma - Results of a metaanalysis [J].
Geschwind, JFH ;
Ramsey, DE ;
Choti, MA ;
Thuluvath, PJ ;
Huncharek, MS .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (04) :344-349
[8]   THE TREATMENT RESPONSES IN CASES OF RADIATION THERAPY TO PORTAL VEIN THROMBOSIS IN ADVANCED HEPATOCELLULAR CARCINOMA [J].
Huang, Yu-Jie ;
Hsu, Hsuan-Chih ;
Wang, Chang-Yu ;
Wang, Chong-Jong ;
Chen, Hui-Chun ;
Huang, Eng-Yen ;
Fang, Fu-Min ;
Lu, Sheng-Nan .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (04) :1155-1163
[9]  
Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21254, 10.3322/caac.21332, 10.3322/caac.21551, 10.3322/caac.20073, 10.3322/caac.21387, 10.3322/caac.21654, 10.3322/caac.21601]
[10]   Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis [J].
Kim, J. H. ;
Yoon, H. -K. ;
Kim, S. Y. ;
Kim, K. M. ;
Ko, G. -Y. ;
Gwon, D. I. ;
Sung, K. -B. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (12) :1291-1298